BPMC News and Press, Blueprint Medicines Corporation From 03/25/22

The European Commission approved the expanded use of Blueprint Medicines' (NASDAQ:BPMC) Ayvakyt (avapritinib) as a monotherapy for adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least o...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis PR Newswire -- AYVAKYT is the first approved therapy in the European Union designed to selectively target the KIT D816...

Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022 -- Blueprint Medicines to host investor conference call and webcast on Friday, April 8, 2022 -- PR Newswire CAMBRIDGE, Mass. , March 8, 2022 /PRNewswire/ -- Blueprint...

Blueprint Medicines (NASDAQ:BPMC) and Proteovant Therapeutics will collaborate on protein degrader therapies and advance up to two candidates into development. The collaboration will utilize Proteovant's artificial intelligence-assisted targeted protein degradation platform and Blueprint Medi...

Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies -- Collaboration will leverage Proteovant's Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines' small...

Shares of Blueprint Medicines (BPMC -5.1%) are down in morning trading after at least two Street firms weighed in on the company's Q4 2021 results released Wednesday. Those results also included a lower-than-expected revenue guidance for 2022. While maintaining a buy rating, H.C. Wainwri...

Blueprint Medicines Corporation (BPMC) Q4 2021 Earnings Conference Call February 16, 2022 8:30 AM ET Company Participants Kristin Hodous – Senior Manager-Investor Relations Jeff Albers – Chief Executive Officer Kate Haviland – Chief Operating Officer Christy Rossi –...

Blueprint Medicines (BPMC -9.1%) is trading sharply lower in the morning hours on Wednesday after the company initiated a lower-than-expected revenue guidance for 2022. Announcing its Q4 2021 results, Blueprint (NASDAQ:BPMC) reported $107M in quarterly revenue, including $20.0M net product re...

The subsector with the best value and quality scores is pharmaceutical/biotechnology. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For February

Blueprint Medicines  press release (NASDAQ:BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25. Revenue of $107M (+213.7% Y/Y) beats by $2.86M. Blueprint Medicines today announced it anticipates approximately $180M to $200M in total revenues in 2022, including approximately $115M to $130M in AY...